HCG and TRT — Laboratory Research Perspective
HCG (human chorionic gonadotropin) is a glycoprotein hormone that acts on the luteinizing hormone receptor (LHCGR). In research settings, HCG is commonly investigated alongside testosterone replacement therapy (TRT) to study interactions between exogenous androgen exposure and the hypothalamic–pituitary–gonadal (HPG) axis.
Research involving HCG and TRT focuses on how LHCGR stimulation and androgen signalling influence reproductive endocrine pathways. Experimental models may examine changes in testicular signalling, steroidogenesis, intratesticular testosterone, and gonadal function under different hormonal conditions.
The combination is therefore of interest in endocrinology, reproductive biology and hormone research, particularly when investigating how gonadotropin signalling interacts with externally supplied testosterone and how these pathways affect downstream biological markers.
Research Areas
- LHCGR receptor signalling
- HPG-axis regulation
- Steroidogenesis pathways
- Intratesticular testosterone research
- Gonadal signalling and function
- Interaction between gonadotropin and androgen pathways
- Hormonal biomarker analysis
- Preclinical endocrine research
Research use only.
Testosterone enanthate has become one of the most popular testosterone preparations used in private TRT clinics across the UK. While Sustanon 250 remains the default NHS prescription for many men, an increasing number of clinicians and patients are choosing enanthate for its predictable pharmacokinetics, excellent blood level stability, and suitability for home self-injection.
This guide explains everything you need to know about testosterone enanthate — what it is, how it works, how it is dosed, and what to expect from treatment. We will also cover side effects, monitoring requirements, availability and cost in the UK, and how enanthate compares to other testosterone formulations.
